Human Genome (HGSI) Trades Well Above GSK Offer, Other Biotechs See Action

April 19, 2012 7:14 AM EDT
Get Alerts HGSI Hot Sheet
Trade HGSI Now!
Join SI Premium – FREE
Shares of Human Genome Sciences Inc. (Nasdaq: HGSI) are trading beyond Glaxo's (NYSE: GSK) rejected $13 per share bid on speculation of a higher bid.

Human Genome last traded at $14.50, up 103 percent.

The news is also boosting other biotech stocks on M&A hopes:

Dendreon Corp. (Nasdaq: DNDN) is up 10%
VIVUS Inc. (Nasdaq: VVUS) is indicated higher.
Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) is indicated higher
InterMune Inc. (Nasdaq: ITMN) is indicated higher

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Rumors, Trader Talk

Add Your Comment